HROW supply chain intelligence for Harrow, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Harrow, Inc. (HROW) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BTIG-LLC | BTIG-LLC | 92% | On March 24, 2026, Harrow, Inc. (the “Company”) entered into a purchase agreement, dated March 24, 2026 (the “Purchase Agreement”) with BTIG, LLC, as representative of the several initial purchasers … |
| U-S-BANK-TRUST-COMPANY-NATIONAL-ASSOCIATION | U-S-BANK-TRUST-COMPANY-NATIONAL-ASSOCIATION | 90% | the Company, the subsidiary guarantors named therein and U.S. Bank Trust Company, National Association, as trustee |
| THREE-MAIN-SUPPLIERS | THREE-MAIN-SUPPLIERS | 80% | The Company received its active pharmaceutical ingredients from three main suppliers during each of the three months ended March 31, 2026 and 2025. |
| CAH | Cardinal Health, Inc. | 72% | uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the availability of scientific and technical inf… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from HROW graph: uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketin… |
| ETON | Eton Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ETON graph: Reciprocal relationship from HROW graph: atient settings where sedation or anxiety management may be beneficial, such as diagnostic imaging, endoscopy and pre… |
| ETON | Eton Pharmaceuticals, Inc. | 72% | atient settings where sedation or anxiety management may be beneficial, such as diagnostic imaging, endoscopy and pre-anesthesia—MELT-300 may provide us the opportunity to expand into procedural seda… |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from HROW graph: uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketin… |
| MCK | McKesson Corporation | 72% | uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the availability of scientific and technical inf… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IHEEZO | IHEEZO | 90% | Other than IHEEZO for the three months ended March 31, 2025 and VEVYE, no other products accounted for more than 10% of total revenues for the periods presented. |
| VEVYE | VEVYE | 90% | Other than IHEEZO for the three months ended March 31, 2025 and VEVYE, no other products accounted for more than 10% of total revenues for the periods presented. |
| CAH | Cardinal Health, Inc. | 72% | uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the availability of scientific and technical inf… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from HROW graph: Reciprocal relationship from CAH graph: Reciprocal relationship from HROW graph: uct relative to alternative products,… |
| ETON | Eton Pharmaceuticals, Inc. | 72% | x’s customer base has grown to include more than 10,000 U.S. eyecare-dedicated prescribers and institutions. 5 Pharmaceutical Compounding Pharmaceutical compounding is the science of combining differ… |
| ETON | Eton Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ETON graph: Reciprocal relationship from HROW graph: x’s customer base has grown to include more than 10,000 U.S. eyecare-dedicated prescribers and institutions. 5 Pharma… |
| MCK | McKesson Corporation | 72% | uct relative to alternative products, the availability of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the availability of scientific and technical inf… |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from HROW graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HROW graph: uct relative to alternative products,… |
| BACKGROUND-HARROW-INC | BACKGROUND-HARROW-INC | 62% | these unaudited condensed consolidated financial statements. 4 HARROW, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 2026 2025 For the Three Months Ended March 31, 2026 2025 CASH FLO… |
| EYEVANCE-PHARMACEUTICALS-LLC | EYEVANCE-PHARMACEUTICALS-LLC | 62% | NOTE 5. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets at March 31, 2026 and December 31, 2025 consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER … |
| HARROW-EYE-LLC | HARROW-EYE-LLC | 62% | and VEVYE, no other products accounted for more than 10% of total revenues for the periods presented. Customer and Supplier Concentrations Substantially all of the Company’s Branded sales are made to… |
| IMPRIMIS-NJOF-LLC | IMPRIMIS-NJOF-LLC | 62% | and VEVYE, no other products accounted for more than 10% of total revenues for the periods presented. Customer and Supplier Concentrations Substantially all of the Company’s Branded sales are made to… |
| IMPRIMISRX-LLC-IMPRIMISRX-NJ-LLC | IMPRIMISRX-LLC-IMPRIMISRX-NJ-LLC | 62% | and VEVYE, no other products accounted for more than 10% of total revenues for the periods presented. Customer and Supplier Concentrations Substantially all of the Company’s Branded sales are made to… |
| MELT-PHARMACEUTICALS-INC | MELT-PHARMACEUTICALS-INC | 62% | nment agencies, wholesalers, distributors, customers, former product owners or other third parties that we believe are unsupported, overstated, duplicative, attributable to another party or product, … |
| SAMSUNG-BIOEPIS-CO-LTD | SAMSUNG-BIOEPIS-CO-LTD | 62% | NOTE 5. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets at March 31, 2026 and December 31, 2025 consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER … |
| SANTEN-PHARMACEUTICALS-CO-LTD | SANTEN-PHARMACEUTICALS-CO-LTD | 62% | NOTE 5. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets at March 31, 2026 and December 31, 2025 consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| HROW-DEBT | Debt stack $300.6M | 90% | Market cache reports total debt of $300.6M. |
| HROW-DEBT-10076 | Warrants outstanding: 60000 | 90% | xbrl warrant detail from xbrl 2020-12-31. |
| HROW-DEBT-10077 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2017-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| HROW-OWNER-OPALEYE-MANAGEMENT-INC | Opaleye Management Inc. | 90% | 13F overlay lists Opaleye Management Inc. as top holder; 219 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CAH | Cardinal Health, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| MCK | McKesson Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| ETON | Eton Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| VEVYE | VEVYE | 60.75 | 1 | ['receiving'] |
| IHEEZO | IHEEZO | 60.75 | 1 | ['receiving'] |
| ORANY | ORANGE | 50.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 50.00 | 2 | |
| CTXR | Citius Pharmaceuticals, Inc. | 50.00 | 2 | |
| SUPN | Supernus Pharmaceuticals, Inc. | 50.00 | 2 | |
| HCSG | Healthcare Services Group, Inc. | 50.00 | 2 | |
| SWKHL | SWK Holdings Corp | 50.00 | 2 | |
| ADCT | ADC Therapeutics SA | 50.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 50.00 | 2 | |
| CLH | Clean Harbors, Inc. | 50.00 | 2 | |
| ARDX | Ardelyx, Inc. | 50.00 | 2 | |
| APO-PA | Apollo Global Management, Inc. | 50.00 | 2 | |
| HCA | HCA Healthcare, Inc. | 50.00 | 2 | |
| HLNCF | Haleon plc | 50.00 | 2 | |
| CRM | Salesforce, Inc. | 50.00 | 2 | |
| AMPH | Amphastar Pharmaceuticals, Inc. | 50.00 | 2 |